FDA fosters development of COVID-19 treatments
The FDA says is has taken action to accelerate the development of prevention and treatment options for COVID-19 by providing new guidance with recommendations for...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
The FDA says is has taken action to accelerate the development of prevention and treatment options for COVID-19 by providing new guidance with recommendations for...
The Jackson Laboratory (JAX), in partnership with the State of Connecticut, is expanding its COVID-19 testing capacity from 550 tests per day to 20,000 tests...
The New Haven City Plan department has proposed updating the city’s zoning laws to allow for larger developments in exchange for more environmentally friendly construction...
Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. RBX2660 is being developed...
Check-In, from BioCT member pwc, is a precision platform made up of two products built with people’s privacy in mind. The platform provides businesses with near real-time...
A New Haven company has been granted up to $1.3 million from a national Alzheimer’s disease accelerator to advance its work developing a mobile app...
Antiviral developer NanoViricides says it has inked a confidential disclosure agreement with a “leading pharmaceutical company” in Asia to explore collaborating on the Shelton company’s proposed COVID-19...
Alexion will acquire Portola, a California-based commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Portola’s commercialized medicine, Andexxa®, is the first and only approved Factor Xa...
BARDA has awarded Tangen Biosciences the Second Option of a contract to develop a molecular diagnostic platform that can be used by the company to rapidly...
Pfizer and BioNTech SE report that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program...